A Six-Week Safety Study of an Investigational Ophthalmic Solution
A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of AL-4943A Ophthalmic Solution Administered Once Daily
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Able and willing to comply with study protocol and follow protocol instructions.
- Adequate birth control methods for the duration of the study.
- Best-corrected visual acuity (BCVA) of 55 or greater in each eye.
- Willing to avoid contact lens wear during each of the study visits; contact lens wear also should be stable and consistent for 1 month prior to Visit 1 and expected to remain the same for the study duration.
- Willing and able to sign an Informed Consent form.
- Other protocol-specified inclusion criteria may apply.
Exclusion Criteria:
- Women of childbearing potential that are pregnant, breastfeeding, or not in agreement to use adequate birth control methods to prevent pregnancy throughout the study.
- Evidence of contact lens care solution related ocular surface damage or giant papillary conjunctivitis (GPC).
- Any ocular infection (bacterial, viral or fungal) or history of ocular Herpes (simplex or zoster) or adenoviral infection in either eye or have had any ocular infection within 30 days prior to Visit 1.
- Using systemic medication(s) on a chronic dosing regimen for less than 30 days or changed dosage of this medication within 30 days prior to Visit 1.
- Current or past history of glaucoma or ocular hypertension.
- History of retinal detachment, diabetic retinopathy, or progressive retinal disease.
- Presence of ocular conditions that may affect the study outcomes.
- Corneal conditions affecting the corneal structure.
- History or evidence of any ocular surgical procedure within 1 year prior to Visit 1.
- Current or recent medical conditions that, in the opinion of the Investigator, would preclude safe participation in the study.
- Prior, current, or anticipated use of ophthalmic agents other than investigational product during study participation.
- Participation in any investigational study within 30 days prior to Visit 1 or concomitantly with this study.
- Known contraindications or hypersensitivities to any of the study medications or their components.
- Other protocol-specified exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: AL-4943A
AL-4943A Ophthalmic Solution, one drop instilled in both eyes once daily for up to 6 weeks
|
|
|
PLACEBO_COMPARATOR: AL-4943A Vehicle
AL-4943A Ophthalmic Solution Vehicle, one drop instilled in both eyes once daily for up to 6 weeks
|
Inactive ingredients used as placebo
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adverse Events
Time Frame: An average of 6 weeks
|
An adverse event was defined as any untoward medical occurrence in a subject administered a study treatment regardless of causal relationship with the treatment.
AEs were obtained as solicited comments from the study subjects and as observations by the study Investigator.
|
An average of 6 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Terri Pasquine, Alcon Research
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Immune System Diseases
- Hypersensitivity, Immediate
- Eye Diseases
- Hypersensitivity
- Conjunctival Diseases
- Conjunctivitis
- Conjunctivitis, Allergic
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Anti-Allergic Agents
- Histamine H1 Antagonists
- Histamine Antagonists
- Histamine Agents
- Histamine H1 Antagonists, Non-Sedating
- Ophthalmic Solutions
- Pharmaceutical Solutions
- Olopatadine Hydrochloride
Other Study ID Numbers
Other Study ID Numbers
- C-12-028
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.